Introduction
Connective tissue diseases (CTDs), including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Myositis, are systemic autoimmune disorders known to involve the heart. While echocardiography is a standard clinical tool for screening complications like pulmonary arterial hypertension (paH), comprehensive data regarding the full spectrum and frequency of cardiac abnormalities across different CTD subtypes has been lacking. This retrospective study quantifies these findings and explores how they evolve over time.
Methods
Researchers conducted a retrospective chart review of 1,004 patients treated at two German tertiary rheumatological referral centers (Berlin-Buch and Bonn) between 2006 and 2015. The analysis encompassed 1,660 echocardiograms. The study focused on three primary objectives:
- Frequency: Determining the proportion of patients with pathological results across various CTD diagnoses.
- Correlation: Assessing the link between current findings and a documented history of inflammatory cardiac involvement.
- Progression: Analyzing longitudinal changes in a subset of 314 patients who underwent multiple examinations over a median interval of 40 months.
Prevalence of Cardiac Abnormalities
The study revealed a high prevalence of cardiac findings across all CTD subtypes. Valvular regurgitation, particularly of the mitral and tricuspid valves, was among the most common observations. Additionally, chamber dilatation and left ventricular (LV) dysfunction were frequently noted.
Key Insights
The Impact of Inflammatory History
A history of inflammatory cardiac involvement served as a significant predictor for current abnormalities. Patients with such a history demonstrated markedly higher rates of several conditions compared to those without:
- Tricuspid Regurgitation: 45.0% vs. 23.2%
- Pericardial Effusion: 43.1% vs. 6.5%
- Signs of paH: 28.4% vs. 5.3%
- Left Atrium Dilatation: 33.9% vs. 17.5%
The Dynamic Nature of CTD Cardiac Involvement
One of the study's most critical findings is that cardiac involvement in CTD is often dynamic rather than static. Over the 40-month follow-up period, many patients developed new pathologies, while others saw previous issues resolve:
- New Developments: Mitral regurgitation (24%), tricuspid regurgitation (21%), and LV dysfunction (20%) frequently emerged during follow-up.
- Resolutions: Conversely, mitral regurgitation resolved in 15% of cases, and tricuspid regurgitation in 16%.
This "fluidity" suggests that cardiac status may fluctuate in tandem with the patient's systemic inflammatory state and response to treatment.
Clinical Implications and Conclusion
The high rate of new-onset cardiac issues (affecting 20-24% of the longitudinal cohort) provides strong evidence for the necessity of regular, long-term echocardiographic monitoring in CTD patients. Because cardiac findings can both develop and resolve, clinical management must be adaptive.
While the retrospective nature of the study presents limitations—such as potential confounding from non-disease-related comorbidities—the results underscore that heart involvement is a frequent and evolving component of connective tissue diseases, requiring vigilant screening to optimize patient outcomes.
Summary updated